Drug Discovery

Gilead Sciences to acquire ADC developer Immunomedics for $21bn

Gilead Sciences has agreed to acquire Immunomedics, a US biopharma company engaged in the development of antibody-drug conjugates (ADCs) for cancer, in a deal worth around $21bn.

Exelixis, NBE join forces for discovery and development of ADCs for cancer

Exelixis and NBE-Therapeutics announced a partnership to discover and develop multiple antibody-drug conjugates (ADCs) for oncology applications by leveraging NBE’s unique expertise and proprietary platforms in ADC discovery, including site-specific conjugation and novel payloads.

Cycle Pharmaceuticals secures $25m debt financing

Cycle Pharmaceuticals, a privately-owned, global, patient-dedicated biotechnology company focused on developing and delivering medicines for rare diseases, today announced that it has executed a definitive agreement for a $25 million credit facility with Deutsche Bank AG.

Grifols to take full ownership of Alkahest in $146m deal

Spanish healthcare company Grifols has agreed to acquire the remaining stake in Alkahest, a Silicon Valley-based biopharma company, for $146m.

InPro 8000 Series Turbidity Sensor

This fiber optic measuring system is based on the backscattered light principle and consequently provides the highest possible performance from low/medium turbidities right through to high suspended particle concentrations.

Kite, HiFiBiO Therapeutics partner to discover novel targets and antibodies against AML

Kite, a Gilead Company and HiFiBiO Therapeutics announced the companies have entered into a two-year research collaboration and license agreement in acute myeloid leukemia (AML).

Gilead, Jounce Therapeutics sign $805m worth licensing deal for JTX-1811

Gilead Sciences has signed an exclusive licensing deal worth up to $805m with Jounce Therapeutics for the latter's immunotherapy candidate JTX-1811.

Ionis to purchase 24% stake in Akcea Therapeutics for $500m

Ionis Pharmaceuticals has signed an agreement to purchase remaining stake in US-based biopharmaceutical company Akcea Therapeutics in a deal valued at around $500m.

BeiGene, Singlomics sign licencing agreement on neutralising Covid-19 antibodies

BeiGene has entered into an exclusive licence agreement with Singlomics (Beijing DanXu) Biopharmaceuticals for neutralising Covid-19 antibodies.